IL-7 (human) AlphaLISA Detection Kit, 5,000 Assay Points

Overview

Formats:

• Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
• Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

• No-wash steps, no separation steps
• ELISA alternative technology
• Sensitive detection
• Broad sample compatibility
• Small sample volume
• Results in less than 3 hours
• Half the time of an ELISA assay

Human Interleukin 7 (IL7) is produced as a precursor maturing into a 152 amino acid glycoprotein. IL7 is mainly produced by non-hematopoietic cells like stroma cells in the bone marrow, the thymus, and in lymphoid tissues. IL7 acts mainly on stem cells and induces proliferation and differentiation of pre-B cells, thymocytes and T cell progenitors and co-stimulates proliferation of mature T-cells with other factors such as IL2. It also protects thymocytes from apoptosis through an increased expression of bcl2. IL7 increases the growth, the development, and the anti-viral activity of both CD4+ and CD8+ cells. Clinical results suggest that IL7 is a potential candidate in the treatment of HIV-patients. IL7 is also implicated in rheumatoid arthritis, chronic colitis, and asthma.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.